Plain-English translation of NCT06697301 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new drug called , given together with a standard immunotherapy called pembrolizumab, can help people with advanced melanoma live longer and have better outcomes than pembrolizumab alone. About 740 patients will be randomly assigned to either receive the new treatment combination or standard treatment plus a placebo (dummy pill). The researchers will measure how well the treatment works and how safe it is.
Advanced melanoma is a serious form of skin cancer, and while current immunotherapy treatments like pembrolizumab help many patients, they don't work for everyone. This trial is testing whether adding this new medication to standard treatment might improve results for more patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new medication plus pembrolizumab, or pembrolizumab plus a placebo. You won't know which group you're in (the study is double-blind). You will have regular visits to the research center for physical exams, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects. The study involves two phases, with the first phase helping doctors find the best dose, and the second phase testing whether that dose works better than placebo.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States